ETX-101 is under clinical development by Encoded Therapeutics and currently in Phase II for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy). According to GlobalData, Phase II drugs for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ETX-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ETX-101 overview

ETX-101 is under development for the treatment of Dravet syndrome. It acts by targeting SCN1A (sodium channel protein). The therapeutic candidate comprises of a recombinant Adeno-associated virus (AAV9) vector capable of restoring SCN1A to normal expression levels. It is administered through intracerebroventricular (ICV) infusion. The therapeutic candidate is developed based on the precision gene therapy platform.

Encoded Therapeutics overview

Encoded Therapeutics is a biotechnology company that discovers and develops gene therapies for the treatment of severe genetic disorders. The company is headquartered in South San Francisco, California, the US.

For a complete picture of ETX-101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.